Stage IV Skin Melanoma Clinical Trial
Official title:
Peptide Vaccine With Glucopyranosyl Lipid A - Stable Oil-in-Water Emulsion (GLA-SE) for Patients With Resected Melanoma: A Pilot Study
Verified date | February 2019 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from MART-1a peptide or antigen may help the body build an effective immune response to kill tumor cells. Giving TLR4 agonist GLA-SE with MART-1 antigen may help increase the immune response to MART-1a antigen.
Status | Completed |
Enrollment | 23 |
Est. completion date | April 11, 2019 |
Est. primary completion date | December 7, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Central pathology review submission; Note: this review for MART-1 positivity is mandatory prior to randomization to confirm eligibility - Human leukocyte antigen (HLA)-A2-positive - Histologic proof of stage II, III or IV melanoma that has been completely resected or completely treated with ablative therapy (ex: stereotactic body radiosurgery, radiofrequency ablation, cryoablation) with no current evidence of disease, as demonstrated by imaging within 2 months (stage III or stage IV; must be computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET]/CT) or 6 months (stage II; may be chest x-ray, CT, MRI, or PET/CT) - Absolute neutrophil count (ANC) >= 1500 mL - Hemoglobin (Hgb) > 10 g/dL - Platelets (PLT) >= 50,000 mL - Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) - Alkaline phosphatase =< 3 x ULN - Ability to provide informed consent - Willingness to return to Mayo Clinic Rochester for follow-up - Life expectancy >= 12 weeks - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 - For women of childbearing potential, a negative serum pregnancy test =< 7 days prior to registration - Willingness to provide mandatory blood samples for correlative research Exclusion Criteria: - Uncontrolled or current infection - Known standard therapy for the patient's disease that is potentially curative or proven capable of extending life expectancy - Known allergy to any of the vaccine or adjuvant components, including eggs - Any of the following prior therapies with interval since most recent treatment: - Chemotherapy =< 4 weeks prior to registration - Biologic or immunologic therapy =< 4 weeks prior to registration - Radiation therapy =< 4 weeks prior to registration - Failure to fully recover from side effects of prior therapy or surgery - Any of the following: - Pregnant women - Nursing women - Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.) - Known immune deficiency, including human immunodeficiency virus (HIV) infection - History of systemic autoimmune disease, as patients with ongoing autoimmunity may be at an increased risk of autoimmune toxicity from the study vaccine - Current or recent (=< 4 weeks) use of immunosuppressive medications including systemic (inhaled, oral, or intravenous [IV]) corticosteroids; Note: use of corticosteroids in doses not exceeding those used for adrenal replacement is acceptable - History of brain metastases; EXCEPTION: patients with a solitary brain metastasis that has been completely resected, and who have no ongoing central nervous system (CNS) symptoms and an MRI documenting no evidence of CNS disease at least 3 months after resection and within 30 days of registration, are eligible for treatment - Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy > 5 years prior to registration, the patient must not be receiving other cancer treatment |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Immunological efficacy of the vaccine preparations against tumor antigen MART-1a will be described as a function of the vaccine immune adjuvant, as measured by the frequency and IFN gamma production of vaccine-peptide specific CTL | Additional markers of immune activation will be described as a function of each vaccine preparation. Each factor will be plotted against time. Each graph will be visually inspected for trends across time. The number of patients with at least a 2-fold change in the number of cells/plasma concentration or with a level that goes from undetectable to detectable after the 1st course will be determined. The marker profile of those who derived an immune response and those who did not will be tabled to visually compare and contrast the pattern of marker-specific responses between these patient groups. | Up to 24 months | |
Primary | Immune response | A patient is considered to have achieved an immune response if there is a 2-fold or more increase from pre-treatment levels in the absolute number of vaccine peptide-specific (MART-1a-specific) CTL as measured by tetramer staining, or if the frequency of MART-1a-specific CTL is initially undetectable (< 0.05% of CD8 T cells) and becomes detectable during the vaccine treatment period. The proportion of successes will be estimated and the exact binomial 95% confidence intervals for the true immune response rate will be calculated. | Up to 24 months | |
Secondary | Adverse event rate, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 | The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01886235 -
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
|
N/A | |
Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Completed |
NCT01989559 -
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
|
Phase 1 | |
Withdrawn |
NCT02812693 -
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
|
Phase 1/Phase 2 | |
Completed |
NCT00026221 -
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT02876068 -
Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00397982 -
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
|
Phase 2 | |
Terminated |
NCT01744171 -
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
|
Phase 1 | |
Terminated |
NCT02748564 -
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT02941744 -
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
|
Phase 1/Phase 2 | |
Completed |
NCT01789827 -
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
|
Early Phase 1 | |
Terminated |
NCT01970527 -
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT02654821 -
Study With T-cel Receptor Gene Therapy in Metastatic Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Completed |
NCT00866177 -
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03719131 -
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
|
Phase 2 | |
Completed |
NCT02716948 -
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
|
Phase 1 |